Onderzoeker
Leo Heyndrickx
Projecten
1 - 3 of 3
- To strengthen Institute of Tropical Medicine Pedro Kouri (IPK, Cuba) and National Institute of Hygiene, Epidemiology and Microbiology (INHEM, Cuba) towards accomplishment of their academic mission through capacity building and scientific co-operation.Vanaf1 jan 2018 → 31 dec 2018
- Strengthening the capacity for research, teaching, policy advice, advocacy and networking of the partners in the field of human and animal health (South-Africa).Vanaf1 jan 2018 → 31 dec 2018
- To strengthen the R&D capacities of the Institute of Tropical Medicine Alexander von Humboldt (Peru) to deliver strategies and/or tools for diagnosis, surveillance and control of infectious diseases.Vanaf1 nov 2017 → 31 dec 2021
Publicaties
1 - 10 van 131
- Hybrid immunity overcomes defective immune response to COVID-19 vaccination in kidney transplant recipients(2024)
Auteurs: Nicolas Gemander, Delphine Kemlin, Stéphanie Depickère, NS Kelkar, P Pannus, Shilpee Sharma, Alexandra Waegemans, Véronique Olislagers, Daphnée Georges, Emilie Dhondt, et al.
Pagina's: 635-648 - Third dose of COVID-19 mRNA vaccine closes the gap in immune response between naïve nursing home residents and healthy adults(2023)
Auteurs: Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Daphnée Georges, Sarah Houben, Véronique Olislagers, Alexandra Waegemans, Stéphane De Craeye, Antoine Francotte, Félicie Chaumont, et al.
Pagina's: 2829-2836 - Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients(2023)
Auteurs: Delphine Kemlin, Nicolas Gemander, Stéphanie Depickère, Véronique Olislagers, Daphnée Georges, Alexandra Waegemans, Pieter Pannus, Anne Lemy, Maria E. Goossens, Isabelle Desombere, et al.
Pagina's: 649-658 - SARS-CoV-2 vaccination elicits broad and potent antibody effector functions to variants of concern in vulnerable populations(2023)
Auteurs: Andrew P Hederman, Harini Natarajan, L Heyndrickx, Kevin Ariën, Joshua A Wiener, Peter F Wright, Evan M. Bloch, Aaron A. R. Tobian, Andrew D Redd, Joel N Blankson, et al.
- Validation of a reporter cell line for flavivirus inhibition assays(2023)
Auteurs: Tatiana M T Rezende, Gabriella Macera, L Heyndrickx, J Michiels, S Coppens, Hendrik Jan Thibaut, Kai Dallmeier, Marjan Van Esbroeck, Johan Neyts, Kevin Ariën, et al.
- Five accelerated schedules for the tick-borne encephalitis vaccine FSME-Immun® in last-minute travellers: an open-label, single-Centre, randomized controlled pilot trial(2023)
Auteurs: Nicole Berens-Riha, Petra Andries, Annelies Aerssens, Quentin Ledure, Yolien Vanderbeken, L Heyndrickx, Els Genbrugge, Achilleas Tsoumanis, Yven Van Herrewege, Kevin Ariën, et al.
- Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients(2022)
Auteurs: Lorenzo Canti, Kevin K Ariën, Isabelle Desombere, Stephanie Humblet-Baron, Pieter Pannus, L Heyndrickx, Aurelie Henry, Sophie Servais, Evelyne Willems, Gregory Ehx, et al.
Pagina's: 335-337 - A high-throughput yellow fever neutralization assay(2022)
Auteurs: Madina Rasulova, Thomas Vercruysse, Jasmine Paulissen, Catherina Coun, Vanessa Suin, L Heyndrickx, Ji Ma, Katrien Geerts, Jolien Timmermans, Niraj Mishra, et al.
- Safety and immunogenicity of a reduced dose of the BNT162b2 mRNA COVID-19 vaccine (REDU-VAC): a single blind, randomized, non-inferiority trial(2022)
Auteurs: Pieter Pannus, Stéphanie Depickère, Delphine Kemlin, Sarah Houben, Kristof Y. Neven, L Heyndrickx, J Michiels, B Willems, Stéphane De Craeye, Antoine Francotte, et al.
Pagina's: e0001308 - Chikungunya virus' high genomic plasticity enables rapid adaptation to restrictive A549 cells(2022)
Auteurs: Lien De Caluwe, L Heyndrickx, S Coppens, K Vereecken, Miguel E Quiñones-Mateu, Andres Merits, Kevin Ariën, Koen Bartholomeeusen